LY235959 attenuates development phase of Methamphetamine-Induced behavioral sensitization through the PP2A/B - AKT cascade in the dorsal striatum of C57/BL6 mice
Copyright © 2022 Elsevier B.V. All rights reserved..
Drug addiction can be described as a chronic and relapsing brain disease. Behavioral sensitization is common animal model in the study of addiction and N-Methyl-D-aspartate subtype of glutamate receptor (NMDAR) is believed play key role in this process. LY235959 is a competitive NMDAR antagonist, however, its effect on methamphetamine (METH)-induced behavioral sensitization is not been reported yet. In this study, we choose three doses (0.33 mg/kg, 1.0 mg/kg, and 3.0 mg/kg) of LY235959 to investigate its effect on locomotor activity, METH-induced behavioral sensitization and different phases of it in C57/BL6 mice. We also used western blotting to examine the PP2A/B - AKT cascade which had been proved involved in METH-induced behavioral sensitization in the dorsal striatum (DS). The results showed that only 0.33 mg/kg LY235959 increased locomotor activity dramatically, however, 1.0 mg/kg and 3.0 mg/kg of LY235959 could attenuate METH-induced behavioral sensitization markedly. We also found that LY235959 only disrupted the development phase of METH-induced behavioral sensitization and the following western blotting results further indicated that PP2A/B - AKT cascade might involve in this process. Taken together, these results indicated that LY235959 attenuates development phase of METH-induced behavioral sensitization through the PP2A/B - AKT cascade in the DS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:776 |
|---|---|
| Enthalten in: |
Neuroscience letters - 776(2022) vom: 17. Apr., Seite 136561 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Gang [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.04.2022 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.neulet.2022.136561 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337714541 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337714541 | ||
| 003 | DE-627 | ||
| 005 | 20231225235039.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.neulet.2022.136561 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1125.xml |
| 035 | |a (DE-627)NLM337714541 | ||
| 035 | |a (NLM)35240244 | ||
| 035 | |a (PII)S0304-3940(22)00118-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Gang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a LY235959 attenuates development phase of Methamphetamine-Induced behavioral sensitization through the PP2A/B - AKT cascade in the dorsal striatum of C57/BL6 mice |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier B.V. All rights reserved. | ||
| 520 | |a Drug addiction can be described as a chronic and relapsing brain disease. Behavioral sensitization is common animal model in the study of addiction and N-Methyl-D-aspartate subtype of glutamate receptor (NMDAR) is believed play key role in this process. LY235959 is a competitive NMDAR antagonist, however, its effect on methamphetamine (METH)-induced behavioral sensitization is not been reported yet. In this study, we choose three doses (0.33 mg/kg, 1.0 mg/kg, and 3.0 mg/kg) of LY235959 to investigate its effect on locomotor activity, METH-induced behavioral sensitization and different phases of it in C57/BL6 mice. We also used western blotting to examine the PP2A/B - AKT cascade which had been proved involved in METH-induced behavioral sensitization in the dorsal striatum (DS). The results showed that only 0.33 mg/kg LY235959 increased locomotor activity dramatically, however, 1.0 mg/kg and 3.0 mg/kg of LY235959 could attenuate METH-induced behavioral sensitization markedly. We also found that LY235959 only disrupted the development phase of METH-induced behavioral sensitization and the following western blotting results further indicated that PP2A/B - AKT cascade might involve in this process. Taken together, these results indicated that LY235959 attenuates development phase of METH-induced behavioral sensitization through the PP2A/B - AKT cascade in the DS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Behavioral sensitization | |
| 650 | 4 | |a LY235959 | |
| 650 | 4 | |a Methamphetamine | |
| 650 | 4 | |a N-Methyl-D-aspartate receptors | |
| 650 | 4 | |a Protein phosphatase 2A | |
| 650 | 7 | |a Central Nervous System Stimulants |2 NLM | |
| 650 | 7 | |a Isoquinolines |2 NLM | |
| 650 | 7 | |a Methamphetamine |2 NLM | |
| 650 | 7 | |a 44RAL3456C |2 NLM | |
| 650 | 7 | |a LY 235959 |2 NLM | |
| 650 | 7 | |a AR2BHC0C6P |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-akt |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Protein Phosphatase 2 |2 NLM | |
| 650 | 7 | |a EC 3.1.3.16 |2 NLM | |
| 700 | 1 | |a Yang, Canyu |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Min |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Jianmin |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Baoyao |e verfasserin |4 aut | |
| 700 | 1 | |a Asif Nazir, Khosa |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Hongyan |e verfasserin |4 aut | |
| 700 | 1 | |a Qiao, Chuchu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xinshe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuroscience letters |d 1975 |g 776(2022) vom: 17. Apr., Seite 136561 |w (DE-627)NLM000386529 |x 1872-7972 |7 nnns |
| 773 | 1 | 8 | |g volume:776 |g year:2022 |g day:17 |g month:04 |g pages:136561 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.neulet.2022.136561 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 776 |j 2022 |b 17 |c 04 |h 136561 | ||